ATE412666T1 - Zusammensetzungen und verfahren zur modulierung von rsv-infektionen und -immunität - Google Patents

Zusammensetzungen und verfahren zur modulierung von rsv-infektionen und -immunität

Info

Publication number
ATE412666T1
ATE412666T1 AT01987765T AT01987765T ATE412666T1 AT E412666 T1 ATE412666 T1 AT E412666T1 AT 01987765 T AT01987765 T AT 01987765T AT 01987765 T AT01987765 T AT 01987765T AT E412666 T1 ATE412666 T1 AT E412666T1
Authority
AT
Austria
Prior art keywords
motif
rsv
immunity
compositions
methods
Prior art date
Application number
AT01987765T
Other languages
English (en)
Inventor
Ralph Tripp
Les Jones
Larry Anderson
Original Assignee
Us Gov Health & Human Serv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22911027&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE412666(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Us Gov Health & Human Serv filed Critical Us Gov Health & Human Serv
Application granted granted Critical
Publication of ATE412666T1 publication Critical patent/ATE412666T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K9/00—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/11—Paramyxoviridae (F); Pneumoviridae (F), e.g. respiratory syncytial virus [RSV]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18522—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pulmonology (AREA)
AT01987765T 2000-10-18 2001-10-18 Zusammensetzungen und verfahren zur modulierung von rsv-infektionen und -immunität ATE412666T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US24152100P 2000-10-18 2000-10-18

Publications (1)

Publication Number Publication Date
ATE412666T1 true ATE412666T1 (de) 2008-11-15

Family

ID=22911027

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01987765T ATE412666T1 (de) 2000-10-18 2001-10-18 Zusammensetzungen und verfahren zur modulierung von rsv-infektionen und -immunität

Country Status (9)

Country Link
US (4) US20040009177A1 (de)
EP (1) EP1334119B2 (de)
AT (1) ATE412666T1 (de)
AU (2) AU2002224416A1 (de)
CA (1) CA2426312C (de)
DE (1) DE60136381D1 (de)
DK (1) DK1334119T4 (de)
ES (1) ES2316487T5 (de)
WO (1) WO2002032942A2 (de)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1768993A4 (de) * 2004-06-16 2008-07-23 Univ Johns Hopkins Cysteinreiche region des humanen respiratorischen synzytial-virus und verwendungsverfahren dafür
MX2008011280A (es) * 2006-03-06 2008-09-12 Symphogen As Anticuerpor policlonal recombinante para el tratamiento de infecciones por el virus sincitial respiratorio.
MX2009009226A (es) * 2007-03-06 2009-10-28 Symphogen As Anticuerpos recombinantes para el tratamiento de infecciones con el virus respiratorio sincitial.
KR101671452B1 (ko) * 2007-10-25 2016-11-17 트렐리스 바이오싸이언스 인코포레이티드 항ｒｓｖ ｇ 단백질 항체
GB0724253D0 (en) * 2007-12-12 2008-01-30 Fermentas Uab Transfection reagent
AU2009236585B2 (en) * 2008-04-18 2013-03-07 Vaxinnate Corporation Deletion mutants of flagellin and methods of use
WO2010075491A2 (en) * 2008-12-24 2010-07-01 University Of Rochester Recombinant expression of self-folding neutralizing epitope-bearing subdomains of the respiratory syncytial virus attachment and fusion proteins
CA2770304C (en) 2009-08-04 2019-11-26 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services, Centers For Disease Control And Prevention Anti-rsv immunogens and methods of immunization
GB0917792D0 (en) * 2009-10-12 2009-11-25 Fermentas Uab Delivery agent
US9856456B2 (en) 2009-10-12 2018-01-02 Thermo Fisher Scientific Baltics Uab Delivery agent
CA2799934C (en) 2010-07-07 2020-01-28 Artificial Cell Technologies, Inc. Respiratory syncytial virus antigenic compositions and methods
MX2013000832A (es) * 2010-07-28 2013-02-11 Nissan Motor Electrodo bipolar, bateria secundaria bipolar que utiliza el mismo y metodo para fabricar electrodo bipolar.
EA201891945A3 (ru) 2012-08-01 2019-05-31 Бавариан Нордик А/С Вакцина рекомбинантного модифицированного вируса осповакцины анкара (mva) респираторно-синцитиального вируса (rsv)
EP2993009A1 (de) * 2014-09-08 2016-03-09 HILTI Aktiengesellschaft Verfahren zur Steuerung eines Wandsägesystems beim Erstellen eines Trennschnittes
SE539731C2 (sv) 2016-03-04 2017-11-14 Vertical Wind Ab Rotor för en elektrisk generator och förfarande för dess tillverkning
US11773143B2 (en) 2017-10-13 2023-10-03 Trellis Bioscience, Llc Conformational epitopes in respiratory syncytial virus G protein central conserved region
EP3833677A4 (de) 2018-08-08 2022-04-27 Trellis Bioscience, Inc. Verbesserte rsv-passive und -aktive impfstoffe
US11201095B1 (en) 2019-08-23 2021-12-14 Xilinx, Inc. Chip package having a cover with window
EP4125936A4 (de) 2020-03-23 2024-03-27 Atossa Therapeutics, Inc. Heparin und n-acetylcystein zur behandlung eines respiratorischen virus

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2718452B1 (fr) † 1994-04-06 1996-06-28 Pf Medicament Elément d'immunogène, agent immunogène, composition pharmaceutique et procédé de préparation.
ATE178906T1 (de) 1994-08-25 1999-04-15 Stichting Inst Dierhouderij Antigene peptide abgeleitet vom g-protein des rsv (respiratorisches synzytialvirus) für die typen- und subtypen spezifische diagnose einer rsv- infektionen
WO1997027299A1 (en) † 1996-01-24 1997-07-31 Schering Corporation Mammalian cx3c chemokine genes
AUPO026596A0 (en) 1996-06-05 1996-06-27 Biomolecular Research Institute Limited Viral peptide
US6020182A (en) * 1996-07-12 2000-02-01 Connaught Laboratories Limited Subunit respiratory syncytial virus vaccine preparation
EP1010692A1 (de) 1997-07-04 2000-06-21 Chisso Corporation Flüssigkristalline verbindungen mit hoher anisotroper durchlässigkeit, flüssigkristalline zusammensetzung die diese verbindungen enthält und flüssigkristallines anzeigeelement, das unter verwendung der flüssigkristallinen zusammensetzung hergestellt wurde
BR9812240A (pt) * 1997-09-19 2000-07-18 American Cyanamid Co Proteìna g alterada ou polipeptìdeo do rsv, uso da mesma, molécula de ácido nucleico codificando uma proteìna g alterada ou um polipeptìdeo do rsv, construção do ácido nucleico, célula hospedeira recombinante, processos de produção de uma proteìna g alterada ou polipeptìdeo do rsv composição imunogênica, de indução de uma resposta imune em um vertebrado, de inibir a indução do aumento da doença após a vacinação e subsequente infecção de um vertebrado com o rsv e de imunização de um vertebrado contra o rsv, composição de vacina, vacina, e, composição imunogênica
FR2827605B1 (fr) 2001-07-20 2004-07-16 Pf Medicament Nouveaux peptides derives de la proteine g du vrs et leur utilisation dans un vaccin

Also Published As

Publication number Publication date
ES2316487T3 (es) 2009-04-16
US20040009177A1 (en) 2004-01-15
EP1334119B2 (de) 2018-11-28
EP1334119A2 (de) 2003-08-13
DE60136381D1 (de) 2008-12-11
ES2316487T5 (es) 2019-05-13
US8173131B2 (en) 2012-05-08
WO2002032942A3 (en) 2002-12-12
DK1334119T4 (en) 2019-03-18
CA2426312C (en) 2014-01-14
AU2009200997A1 (en) 2009-04-02
US8778354B2 (en) 2014-07-15
EP1334119B1 (de) 2008-10-29
AU2009200997B2 (en) 2011-12-22
US20140288267A1 (en) 2014-09-25
US20060018925A1 (en) 2006-01-26
WO2002032942A2 (en) 2002-04-25
US20120258111A1 (en) 2012-10-11
DK1334119T3 (da) 2009-02-23
AU2002224416A1 (en) 2002-04-29
CA2426312A1 (en) 2002-04-25

Similar Documents

Publication Publication Date Title
DE60136381D1 (de) Zusammensetzungen und verfahren zur modulierung von rsv-infektionen und -immunität
ATE310089T1 (de) Von dem syndrom der weissen flecken virus abgeleitete proteine und deren verwendungen
MY138860A (en) Hiv protease inhibitors.
ATE475423T1 (de) Immunostimulierende polynukleotide sequenzen zur verwendung bei der verhinderung und behandlung von viralen erkrankungen
ATE327246T1 (de) Hepatitis c tripeptid inhibitoren
BRPI0306993B8 (pt) polímero de polialquilenoglicol ativado; composição; e uso de um composto na produção de um medicamento para o tratamento de esclerose múltipla ou infecção viral suscetível
AU2002248384A1 (en) Serpin drugs for treatment of hiv infection and method of use thereof
ATE497775T1 (de) Verwendung einer kombination von cyclosporin und pegylierten interferonen zur behandlung von hepatitis c (hcv)
IS7533A (is) Lifrarbólgu C-veirutálmar
ES2132201T3 (es) Inhibidores de la hiv proteasa utiles en el tratamiento del sida.
ATE413411T1 (de) Substituierte cycloalkyl p1' hepatitis c virus inhibitoren
MXPA02012443A (es) Profarmaco en 3'' de 2'-desoxi-beta-l-nucleosidos.
DK1479691T3 (da) Langvarigt aktive fuionspeptidinhibitorer for HIV infektion
MA27699A1 (fr) Vaccin contre vhc
DE69518840D1 (en) N-(3-amino-2-hydroxybutyl)sulfonamid-derivate as hiv-protease-inhibitoren
DE60137146D1 (de) Fusionszellen und zytokin-zusammensetzungen zur behandlung von krankheiten
AR005750A1 (es) Composicion farmaceutica para tratar o prevenir infecciones con zoster en personas infectadas con el virus de varicela zoster y procedimiento para preparar dicha composicion
ATE486088T1 (de) Hiv-impfstoff
DE60104815D1 (de) Bakteriophagen-assoziierte lytische enzyme zur therapeutischen behandlung von bakteriellen infektionen
DE60236443D1 (de) Inhibitoren der kostimulation via ox40 und deren verwendung gegen eine von virusen induzierten immunpathologie
WO2006109174A3 (en) Hiv vaccine comprising a glycoprotein 120 signal sequence with no more than one positively charged amino acid
DE69932741D1 (de) Verwendung von n-glycolneuraminsäure und deren derivaten zur herstellung eines medikaments zur behandlung von hiv-infektionen
ATE411812T1 (de) Peptide zur behandlung von infektionen mit dem herpes-virus
ATE237616T1 (de) Verwendung von (1r,4s)-4-(6-amino-9h-purin-9-yl)- 2-cyclopenten-1-methanol in hbv
ATE408421T1 (de) Pna-konjugat zur therapie von mit hiv in zusammenhang stehenden erkrankungen

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties